Skip to main content
Top
Published in: International Journal of Hematology 5/2014

01-11-2014 | Case Report

Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation

Authors: Hideki Tsujimura, Toshiko Miyaki, Shuhei Yamada, Takeaki Sugawara, Mikiko Ise, Shintaro Iwata, Tsukasa Yonemoto, Dai Ikebe, Makiko Itami, Kyoya Kumagai

Published in: International Journal of Hematology | Issue 5/2014

Login to get access

Abstract

Histiocytic sarcoma (HS) is an extremely rare malignant neoplasm that often exhibits an aggressive clinical presentation. In this report, we describe the case of a 38-year-old female with advanced-stage HS who was found to have a subcutaneous tumor in the left calf and enlarged lymph nodes in the left inguinal and internal iliac regions. The subcutaneous tumor and inguinal nodes were resected operatively. Immunohistochemistry of the surgical specimens showed that the malignant cells stained positive for CD163, CD68, and related markers; a diagnosis of HS was established. Following the administration of induction chemotherapy consisting of dose-escalated CHOP plus etoposide, the remaining internal iliac tumors disappeared. At that point, high-dose chemotherapy with autologous stem cell transplantation was performed as consolidation treatment. The patient remains alive with no evidence of disease for 30 months post-treatment. This report provides valuable insight into the treatment of advanced HS.
Literature
1.
go back to reference Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28:1133–44.PubMedCrossRef Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28:1133–44.PubMedCrossRef
2.
go back to reference Takahashi E, Nakamura S. Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53:1–8.PubMedCrossRef Takahashi E, Nakamura S. Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53:1–8.PubMedCrossRef
3.
go back to reference Grogan TM, Pileri S, Chan JKC. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 356–7. Grogan TM, Pileri S, Chan JKC. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 356–7.
4.
go back to reference Morimoto A, Shimazaki C, Takahashi S, et al. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the special C regimen formulated by the Japan LCH study group. Int J Hematol. 2013;97:103–8.PubMedCrossRef Morimoto A, Shimazaki C, Takahashi S, et al. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the special C regimen formulated by the Japan LCH study group. Int J Hematol. 2013;97:103–8.PubMedCrossRef
5.
go back to reference Kumagai K, Tsuimura H, Sakai C, Takagi T. CHOP-ABVP therapy and upfront autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of aggressive non-Hodgkin’s lymphoma (NHL): a pilot study. Ann Oncol. 1999;10(Suppl 3):163. Kumagai K, Tsuimura H, Sakai C, Takagi T. CHOP-ABVP therapy and upfront autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of aggressive non-Hodgkin’s lymphoma (NHL): a pilot study. Ann Oncol. 1999;10(Suppl 3):163.
6.
go back to reference Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18:693–704.PubMedCrossRef Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18:693–704.PubMedCrossRef
7.
go back to reference Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.PubMedCrossRef Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.PubMedCrossRef
8.
go back to reference Abu-Sanad A, Warsi A, Michel RP, et al. Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma. Curr Oncol. 2012;19:e289–91.PubMedCentralPubMedCrossRef Abu-Sanad A, Warsi A, Michel RP, et al. Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma. Curr Oncol. 2012;19:e289–91.PubMedCentralPubMedCrossRef
9.
go back to reference Gergis U, Dax H, Ritchie E, et al. Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature. J Clin Oncol. 2011;29:e251–3.PubMedCrossRef Gergis U, Dax H, Ritchie E, et al. Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature. J Clin Oncol. 2011;29:e251–3.PubMedCrossRef
10.
go back to reference Zeidan A, Bolanos-Meade J, Kasamon Y, et al. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013;54:655–7.PubMedCrossRef Zeidan A, Bolanos-Meade J, Kasamon Y, et al. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013;54:655–7.PubMedCrossRef
11.
go back to reference Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–93.PubMedCrossRef Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–93.PubMedCrossRef
12.
go back to reference Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.PubMedCrossRef Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.PubMedCrossRef
13.
go back to reference Mainardi C, D’Amore ES, Pillon M, et al. A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant. Leuk Lymphoma. 2011;52:1367–71.PubMedCrossRef Mainardi C, D’Amore ES, Pillon M, et al. A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant. Leuk Lymphoma. 2011;52:1367–71.PubMedCrossRef
14.
go back to reference Kawabata KC, Hagiwara S, Takenouchi A, et al. Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases. Intern Med. 2009;48:111–4.PubMedCrossRef Kawabata KC, Hagiwara S, Takenouchi A, et al. Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases. Intern Med. 2009;48:111–4.PubMedCrossRef
15.
go back to reference Takasaki H, Hashimoto C, Fujita A, et al. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. Clin Lymphoma Myeloma Leuk. 2013;13:404–9.PubMedCrossRef Takasaki H, Hashimoto C, Fujita A, et al. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. Clin Lymphoma Myeloma Leuk. 2013;13:404–9.PubMedCrossRef
16.
go back to reference Tateishi U. PET/CT in malignant lymphoma: basic information, clinical application, and proposal. Int J Hematol. 2013;98:398–405.PubMedCrossRef Tateishi U. PET/CT in malignant lymphoma: basic information, clinical application, and proposal. Int J Hematol. 2013;98:398–405.PubMedCrossRef
17.
go back to reference Abidi MH, Tove I, Ibrahim RB, et al. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007;82:932–3.PubMedCrossRef Abidi MH, Tove I, Ibrahim RB, et al. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007;82:932–3.PubMedCrossRef
18.
go back to reference Shukla N, Kobos R, Renaud T, et al. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer. 2012;118:3719–24.PubMedCrossRef Shukla N, Kobos R, Renaud T, et al. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer. 2012;118:3719–24.PubMedCrossRef
Metadata
Title
Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation
Authors
Hideki Tsujimura
Toshiko Miyaki
Shuhei Yamada
Takeaki Sugawara
Mikiko Ise
Shintaro Iwata
Tsukasa Yonemoto
Dai Ikebe
Makiko Itami
Kyoya Kumagai
Publication date
01-11-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1630-y

Other articles of this Issue 5/2014

International Journal of Hematology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine